14 Jun 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

FluoGuide appoints new CFO

Press release

August 31, 2022

Copenhagen, Denmark, 31 August 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) has today appointed Henrik Hang as Chief Financial Officer (“CFO”). Henrik Hang has substantial experience as CFO from international companies to biotech company listed on Nasdaq First North Growth Market, Stockholm.

Henrik Hang comes most recently from the role as CFO at Cyxone AB (publ). Henrik Hang has a degree in finance from University of Linné, Sweden and will be part of FluoGuide´s management team. Henrik Hang will start at FluoGuide on the 15th of November 2022.

Henrik Hang will replace the current CFO Henrik Moltke, who wished to step down as CFO to devote more time on board work and family. Henrik Moltke will continue as senior advisor for the company with special focus on investor relations and communication.

Morten Albrechtsen, CEO says” I am very glad to welcome Henrik as our new CFO that will give a strong financial management from public companies, I am also happy that we can continue draw on Henrik Moltke’s broad experience within IR as senior advisor”.

For further information, please contact:

Morten Albrechtsen, CEO,
FluoGuide A/S
+45 24 25 62 66,

Certified Adviser:

Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51

About FluoGuide
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is has demonstrated efficacy of F001 as well as it to be well tolerated and safe in the proof-of-concept clinical study (phase I/II) in patients with high grade glioma undergoing surgery. FluoGuide has decided to explore FG001 in three other severe cancer indications, namely lung, head & neck, meningioma and low grade glioma. FluoGuide is listed on Nasdaq First North Growth Market, Sweden under the ticker “FLUO”.

For more information on the Company’s uPAR technology platform and our pipeline please visit our home page